nodes	percent_of_prediction	percent_of_DWPC	metapath
Ergotamine—ABCB1—Mitomycin—urinary bladder cancer	0.186	0.317	CbGbCtD
Ergotamine—ADRA1B—vas deferens—urinary bladder cancer	0.0871	0.404	CbGeAlD
Ergotamine—CYP3A4—Thiotepa—urinary bladder cancer	0.0844	0.144	CbGbCtD
Ergotamine—ABCB1—Gemcitabine—urinary bladder cancer	0.0535	0.0912	CbGbCtD
Ergotamine—CYP1A2—Fluorouracil—urinary bladder cancer	0.0523	0.0892	CbGbCtD
Ergotamine—CYP1A2—Etoposide—urinary bladder cancer	0.0437	0.0745	CbGbCtD
Ergotamine—ABCB1—Cisplatin—urinary bladder cancer	0.0389	0.0663	CbGbCtD
Ergotamine—ABCB1—Etoposide—urinary bladder cancer	0.0382	0.0651	CbGbCtD
Ergotamine—ABCB1—Doxorubicin—urinary bladder cancer	0.026	0.0444	CbGbCtD
Ergotamine—ABCB1—Methotrexate—urinary bladder cancer	0.0252	0.043	CbGbCtD
Ergotamine—CYP3A4—Etoposide—urinary bladder cancer	0.0229	0.039	CbGbCtD
Ergotamine—CYP3A4—Doxorubicin—urinary bladder cancer	0.0156	0.0266	CbGbCtD
Ergotamine—Gangrene—Gemcitabine—urinary bladder cancer	0.0154	0.101	CcSEcCtD
Ergotamine—CYP1A2—urine—urinary bladder cancer	0.0101	0.0467	CbGeAlD
Ergotamine—Paresthesia of limbs—Methotrexate—urinary bladder cancer	0.00897	0.0586	CcSEcCtD
Ergotamine—HTR2A—urine—urinary bladder cancer	0.00787	0.0365	CbGeAlD
Ergotamine—Emotional distress—Fluorouracil—urinary bladder cancer	0.00777	0.0508	CcSEcCtD
Ergotamine—ADRA1D—prostate gland—urinary bladder cancer	0.00761	0.0353	CbGeAlD
Ergotamine—CYP3A4—urine—urinary bladder cancer	0.00728	0.0338	CbGeAlD
Ergotamine—ADRA1D—epithelium—urinary bladder cancer	0.00559	0.0259	CbGeAlD
Ergotamine—ADRA1B—renal system—urinary bladder cancer	0.0053	0.0246	CbGeAlD
Ergotamine—ADRA1D—urethra—urinary bladder cancer	0.00509	0.0236	CbGeAlD
Ergotamine—ADRA1A—prostate gland—urinary bladder cancer	0.00437	0.0203	CbGeAlD
Ergotamine—Myalgia—Valrubicin—urinary bladder cancer	0.00429	0.028	CcSEcCtD
Ergotamine—ADRA1D—female reproductive system—urinary bladder cancer	0.00415	0.0193	CbGeAlD
Ergotamine—Cyanosis—Etoposide—urinary bladder cancer	0.00405	0.0265	CcSEcCtD
Ergotamine—Numbness—Fluorouracil—urinary bladder cancer	0.00399	0.026	CcSEcCtD
Ergotamine—Sensory loss—Fluorouracil—urinary bladder cancer	0.00381	0.0249	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Valrubicin—urinary bladder cancer	0.00375	0.0245	CcSEcCtD
Ergotamine—HTR2B—smooth muscle tissue—urinary bladder cancer	0.00375	0.0174	CbGeAlD
Ergotamine—Numbness—Etoposide—urinary bladder cancer	0.00346	0.0226	CcSEcCtD
Ergotamine—ADRA2A—prostate gland—urinary bladder cancer	0.00332	0.0154	CbGeAlD
Ergotamine—Sensory loss—Etoposide—urinary bladder cancer	0.00331	0.0216	CcSEcCtD
Ergotamine—Pain—Carboplatin—urinary bladder cancer	0.00326	0.0213	CcSEcCtD
Ergotamine—HTR1A—renal system—urinary bladder cancer	0.00323	0.015	CbGeAlD
Ergotamine—ADRA1A—epithelium—urinary bladder cancer	0.00321	0.0149	CbGeAlD
Ergotamine—HTR1B—female reproductive system—urinary bladder cancer	0.00321	0.0149	CbGeAlD
Ergotamine—HTR1D—female reproductive system—urinary bladder cancer	0.0031	0.0144	CbGeAlD
Ergotamine—HTR2C—female reproductive system—urinary bladder cancer	0.00307	0.0143	CbGeAlD
Ergotamine—Hypertension—Mitomycin—urinary bladder cancer	0.003	0.0196	CcSEcCtD
Ergotamine—ADRA1A—renal system—urinary bladder cancer	0.00298	0.0138	CbGeAlD
Ergotamine—Asthenia—Valrubicin—urinary bladder cancer	0.00295	0.0193	CcSEcCtD
Ergotamine—Pruritus—Valrubicin—urinary bladder cancer	0.00291	0.019	CcSEcCtD
Ergotamine—HTR2B—female reproductive system—urinary bladder cancer	0.00289	0.0134	CbGeAlD
Ergotamine—ADRA2A—seminal vesicle—urinary bladder cancer	0.00281	0.013	CbGeAlD
Ergotamine—Vomiting—Valrubicin—urinary bladder cancer	0.00262	0.0171	CcSEcCtD
Ergotamine—HTR2B—vagina—urinary bladder cancer	0.00261	0.0121	CbGeAlD
Ergotamine—SLC6A2—female reproductive system—urinary bladder cancer	0.00257	0.0119	CbGeAlD
Ergotamine—CYP1A2—renal system—urinary bladder cancer	0.00246	0.0114	CbGeAlD
Ergotamine—Nausea—Valrubicin—urinary bladder cancer	0.00244	0.016	CcSEcCtD
Ergotamine—Cyanosis—Methotrexate—urinary bladder cancer	0.00243	0.0159	CcSEcCtD
Ergotamine—Pain—Mitomycin—urinary bladder cancer	0.00242	0.0158	CcSEcCtD
Ergotamine—ADRA2A—urethra—urinary bladder cancer	0.00222	0.0103	CbGeAlD
Ergotamine—HTR2A—epithelium—urinary bladder cancer	0.00208	0.00963	CbGeAlD
Ergotamine—Asthenia—Mitomycin—urinary bladder cancer	0.00203	0.0133	CcSEcCtD
Ergotamine—HTR2A—smooth muscle tissue—urinary bladder cancer	0.002	0.00928	CbGeAlD
Ergotamine—HTR2A—renal system—urinary bladder cancer	0.00193	0.00894	CbGeAlD
Ergotamine—ABCB1—prostate gland—urinary bladder cancer	0.00185	0.00859	CbGeAlD
Ergotamine—ADRA2A—female reproductive system—urinary bladder cancer	0.00181	0.00842	CbGeAlD
Ergotamine—Vomiting—Mitomycin—urinary bladder cancer	0.0018	0.0118	CcSEcCtD
Ergotamine—CYP3A4—renal system—urinary bladder cancer	0.00178	0.00827	CbGeAlD
Ergotamine—HTR2B—lymph node—urinary bladder cancer	0.00169	0.00784	CbGeAlD
Ergotamine—Nausea—Mitomycin—urinary bladder cancer	0.00168	0.011	CcSEcCtD
Ergotamine—Hypoaesthesia—Fluorouracil—urinary bladder cancer	0.00165	0.0108	CcSEcCtD
Ergotamine—ADRA2A—vagina—urinary bladder cancer	0.00164	0.00761	CbGeAlD
Ergotamine—Bradycardia—Cisplatin—urinary bladder cancer	0.0016	0.0105	CcSEcCtD
Ergotamine—ABCB1—seminal vesicle—urinary bladder cancer	0.00157	0.00727	CbGeAlD
Ergotamine—HTR2A—female reproductive system—urinary bladder cancer	0.00154	0.00716	CbGeAlD
Ergotamine—Hypertension—Thiotepa—urinary bladder cancer	0.00151	0.00985	CcSEcCtD
Ergotamine—SLC6A2—lymph node—urinary bladder cancer	0.0015	0.00696	CbGeAlD
Ergotamine—Myalgia—Thiotepa—urinary bladder cancer	0.00149	0.00972	CcSEcCtD
Ergotamine—Hypoaesthesia—Etoposide—urinary bladder cancer	0.00143	0.00937	CcSEcCtD
Ergotamine—CYP3A4—female reproductive system—urinary bladder cancer	0.00143	0.00662	CbGeAlD
Ergotamine—HTR2A—vagina—urinary bladder cancer	0.00139	0.00647	CbGeAlD
Ergotamine—Tachycardia—Thiotepa—urinary bladder cancer	0.00139	0.00909	CcSEcCtD
Ergotamine—ABCB1—epithelium—urinary bladder cancer	0.00136	0.00631	CbGeAlD
Ergotamine—Musculoskeletal discomfort—Thiotepa—urinary bladder cancer	0.0013	0.00849	CcSEcCtD
Ergotamine—Paraesthesia—Thiotepa—urinary bladder cancer	0.00128	0.00836	CcSEcCtD
Ergotamine—Hypertension—Gemcitabine—urinary bladder cancer	0.00127	0.00829	CcSEcCtD
Ergotamine—ABCB1—renal system—urinary bladder cancer	0.00126	0.00586	CbGeAlD
Ergotamine—Myalgia—Gemcitabine—urinary bladder cancer	0.00125	0.00817	CcSEcCtD
Ergotamine—ABCB1—urethra—urinary bladder cancer	0.00124	0.00575	CbGeAlD
Ergotamine—Myalgia—Fluorouracil—urinary bladder cancer	0.00123	0.00804	CcSEcCtD
Ergotamine—Pain—Thiotepa—urinary bladder cancer	0.00122	0.00796	CcSEcCtD
Ergotamine—Myalgia—Cisplatin—urinary bladder cancer	0.00117	0.00762	CcSEcCtD
Ergotamine—Tachycardia—Fluorouracil—urinary bladder cancer	0.00115	0.00752	CcSEcCtD
Ergotamine—Vertigo—Etoposide—urinary bladder cancer	0.00113	0.00736	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Gemcitabine—urinary bladder cancer	0.00109	0.00714	CcSEcCtD
Ergotamine—Tachycardia—Cisplatin—urinary bladder cancer	0.00109	0.00713	CcSEcCtD
Ergotamine—Hypertension—Etoposide—urinary bladder cancer	0.00108	0.00708	CcSEcCtD
Ergotamine—Paraesthesia—Gemcitabine—urinary bladder cancer	0.00108	0.00703	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Fluorouracil—urinary bladder cancer	0.00107	0.00702	CcSEcCtD
Ergotamine—ADRA2A—lymph node—urinary bladder cancer	0.00106	0.00492	CbGeAlD
Ergotamine—Paraesthesia—Fluorouracil—urinary bladder cancer	0.00106	0.00692	CcSEcCtD
Ergotamine—Pain—Gemcitabine—urinary bladder cancer	0.00103	0.0067	CcSEcCtD
Ergotamine—Asthenia—Thiotepa—urinary bladder cancer	0.00102	0.00668	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.00102	0.00665	CcSEcCtD
Ergotamine—ABCB1—female reproductive system—urinary bladder cancer	0.00101	0.00469	CbGeAlD
Ergotamine—Pruritus—Thiotepa—urinary bladder cancer	0.00101	0.00659	CcSEcCtD
Ergotamine—Pain—Fluorouracil—urinary bladder cancer	0.00101	0.00659	CcSEcCtD
Ergotamine—Paraesthesia—Cisplatin—urinary bladder cancer	0.001	0.00656	CcSEcCtD
Ergotamine—Tachycardia—Etoposide—urinary bladder cancer	0.000999	0.00653	CcSEcCtD
Ergotamine—Pain—Cisplatin—urinary bladder cancer	0.000956	0.00624	CcSEcCtD
Ergotamine—Paraesthesia—Etoposide—urinary bladder cancer	0.000919	0.00601	CcSEcCtD
Ergotamine—ABCB1—vagina—urinary bladder cancer	0.000914	0.00424	CbGeAlD
Ergotamine—Vomiting—Thiotepa—urinary bladder cancer	0.000906	0.00592	CcSEcCtD
Ergotamine—Pain—Etoposide—urinary bladder cancer	0.000876	0.00572	CcSEcCtD
Ergotamine—Asthenia—Gemcitabine—urinary bladder cancer	0.00086	0.00562	CcSEcCtD
Ergotamine—Pruritus—Gemcitabine—urinary bladder cancer	0.000848	0.00554	CcSEcCtD
Ergotamine—Nausea—Thiotepa—urinary bladder cancer	0.000847	0.00553	CcSEcCtD
Ergotamine—Pruritus—Fluorouracil—urinary bladder cancer	0.000834	0.00545	CcSEcCtD
Ergotamine—Bradycardia—Epirubicin—urinary bladder cancer	0.000822	0.00537	CcSEcCtD
Ergotamine—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.000804	0.00525	CcSEcCtD
Ergotamine—Asthenia—Cisplatin—urinary bladder cancer	0.000802	0.00524	CcSEcCtD
Ergotamine—Vomiting—Gemcitabine—urinary bladder cancer	0.000762	0.00498	CcSEcCtD
Ergotamine—Bradycardia—Doxorubicin—urinary bladder cancer	0.000761	0.00497	CcSEcCtD
Ergotamine—Vomiting—Fluorouracil—urinary bladder cancer	0.00075	0.0049	CcSEcCtD
Ergotamine—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000744	0.00486	CcSEcCtD
Ergotamine—Asthenia—Etoposide—urinary bladder cancer	0.000735	0.0048	CcSEcCtD
Ergotamine—Pruritus—Etoposide—urinary bladder cancer	0.000724	0.00473	CcSEcCtD
Ergotamine—Nausea—Gemcitabine—urinary bladder cancer	0.000712	0.00465	CcSEcCtD
Ergotamine—Vomiting—Cisplatin—urinary bladder cancer	0.000711	0.00464	CcSEcCtD
Ergotamine—Nausea—Fluorouracil—urinary bladder cancer	0.0007	0.00458	CcSEcCtD
Ergotamine—Vertigo—Methotrexate—urinary bladder cancer	0.000675	0.00441	CcSEcCtD
Ergotamine—Nausea—Cisplatin—urinary bladder cancer	0.000664	0.00434	CcSEcCtD
Ergotamine—Vomiting—Etoposide—urinary bladder cancer	0.000651	0.00425	CcSEcCtD
Ergotamine—Myalgia—Methotrexate—urinary bladder cancer	0.00064	0.00418	CcSEcCtD
Ergotamine—Vertigo—Epirubicin—urinary bladder cancer	0.000632	0.00413	CcSEcCtD
Ergotamine—Nausea—Etoposide—urinary bladder cancer	0.000608	0.00397	CcSEcCtD
Ergotamine—Hypertension—Epirubicin—urinary bladder cancer	0.000607	0.00397	CcSEcCtD
Ergotamine—Myalgia—Epirubicin—urinary bladder cancer	0.000599	0.00391	CcSEcCtD
Ergotamine—ABCB1—lymph node—urinary bladder cancer	0.000591	0.00274	CbGeAlD
Ergotamine—Vertigo—Doxorubicin—urinary bladder cancer	0.000585	0.00382	CcSEcCtD
Ergotamine—Hypertension—Doxorubicin—urinary bladder cancer	0.000562	0.00367	CcSEcCtD
Ergotamine—Tachycardia—Epirubicin—urinary bladder cancer	0.00056	0.00366	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000559	0.00365	CcSEcCtD
Ergotamine—Myalgia—Doxorubicin—urinary bladder cancer	0.000554	0.00362	CcSEcCtD
Ergotamine—Paraesthesia—Methotrexate—urinary bladder cancer	0.000551	0.0036	CcSEcCtD
Ergotamine—Pain—Methotrexate—urinary bladder cancer	0.000524	0.00343	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000523	0.00342	CcSEcCtD
Ergotamine—Tachycardia—Doxorubicin—urinary bladder cancer	0.000518	0.00339	CcSEcCtD
Ergotamine—Paraesthesia—Epirubicin—urinary bladder cancer	0.000515	0.00337	CcSEcCtD
Ergotamine—Pain—Epirubicin—urinary bladder cancer	0.000491	0.00321	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000484	0.00316	CcSEcCtD
Ergotamine—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000477	0.00312	CcSEcCtD
Ergotamine—Pain—Doxorubicin—urinary bladder cancer	0.000454	0.00297	CcSEcCtD
Ergotamine—Asthenia—Methotrexate—urinary bladder cancer	0.00044	0.00288	CcSEcCtD
Ergotamine—Pruritus—Methotrexate—urinary bladder cancer	0.000434	0.00284	CcSEcCtD
Ergotamine—Asthenia—Epirubicin—urinary bladder cancer	0.000412	0.00269	CcSEcCtD
Ergotamine—Pruritus—Epirubicin—urinary bladder cancer	0.000406	0.00265	CcSEcCtD
Ergotamine—Vomiting—Methotrexate—urinary bladder cancer	0.00039	0.00255	CcSEcCtD
Ergotamine—Asthenia—Doxorubicin—urinary bladder cancer	0.000381	0.00249	CcSEcCtD
Ergotamine—Pruritus—Doxorubicin—urinary bladder cancer	0.000376	0.00245	CcSEcCtD
Ergotamine—Vomiting—Epirubicin—urinary bladder cancer	0.000365	0.00238	CcSEcCtD
Ergotamine—Nausea—Methotrexate—urinary bladder cancer	0.000364	0.00238	CcSEcCtD
Ergotamine—Nausea—Epirubicin—urinary bladder cancer	0.000341	0.00223	CcSEcCtD
Ergotamine—Vomiting—Doxorubicin—urinary bladder cancer	0.000338	0.00221	CcSEcCtD
Ergotamine—Nausea—Doxorubicin—urinary bladder cancer	0.000315	0.00206	CcSEcCtD
Ergotamine—HTR1B—Signaling Pathways—CCND1—urinary bladder cancer	9.58e-06	0.000213	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—ESR1—urinary bladder cancer	9.52e-06	0.000212	CbGpPWpGaD
Ergotamine—HTR1E—Signaling Pathways—TP53—urinary bladder cancer	9.5e-06	0.000211	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—MMP9—urinary bladder cancer	9.5e-06	0.000211	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling by GPCR—KRAS—urinary bladder cancer	9.48e-06	0.000211	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—ERBB2—urinary bladder cancer	9.47e-06	0.000211	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—CDKN1A—urinary bladder cancer	9.46e-06	0.000211	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—PTEN—urinary bladder cancer	9.44e-06	0.00021	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—TYMS—urinary bladder cancer	9.42e-06	0.00021	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	9.41e-06	0.000209	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—CREBBP—urinary bladder cancer	9.39e-06	0.000209	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—GSTM1—urinary bladder cancer	9.31e-06	0.000207	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—NCOR1—urinary bladder cancer	9.31e-06	0.000207	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—MMP9—urinary bladder cancer	9.3e-06	0.000207	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—ENO2—urinary bladder cancer	9.28e-06	0.000207	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	9.28e-06	0.000207	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—IGF1—urinary bladder cancer	9.27e-06	0.000206	CbGpPWpGaD
Ergotamine—ADRA2A—Metabolism—CREBBP—urinary bladder cancer	9.27e-06	0.000206	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—CDKN1A—urinary bladder cancer	9.26e-06	0.000206	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—PTEN—urinary bladder cancer	9.24e-06	0.000206	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—RHOA—urinary bladder cancer	9.24e-06	0.000206	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—IL2—urinary bladder cancer	9.23e-06	0.000205	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling by GPCR—EGFR—urinary bladder cancer	9.23e-06	0.000205	CbGpPWpGaD
Ergotamine—HTR1A—Signaling by GPCR—KRAS—urinary bladder cancer	9.15e-06	0.000204	CbGpPWpGaD
Ergotamine—HTR2C—Signaling by GPCR—KRAS—urinary bladder cancer	9.11e-06	0.000203	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—FGFR3—urinary bladder cancer	9.1e-06	0.000203	CbGpPWpGaD
Ergotamine—HTR1E—Signaling Pathways—HRAS—urinary bladder cancer	9.09e-06	0.000202	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	9e-06	0.0002	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—EP300—urinary bladder cancer	9e-06	0.0002	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—CCND1—urinary bladder cancer	9e-06	0.0002	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—CXCL8—urinary bladder cancer	8.99e-06	0.0002	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling by GPCR—HRAS—urinary bladder cancer	8.93e-06	0.000199	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—RHOA—urinary bladder cancer	8.92e-06	0.000198	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—GPX1—urinary bladder cancer	8.91e-06	0.000198	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—RHOA—urinary bladder cancer	8.87e-06	0.000197	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—ESR1—urinary bladder cancer	8.84e-06	0.000197	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—EP300—urinary bladder cancer	8.82e-06	0.000196	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—SRC—urinary bladder cancer	8.75e-06	0.000195	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—ERCC2—urinary bladder cancer	8.75e-06	0.000195	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—MMP9—urinary bladder cancer	8.73e-06	0.000194	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling by GPCR—KRAS—urinary bladder cancer	8.72e-06	0.000194	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—CDKN1A—urinary bladder cancer	8.7e-06	0.000194	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—PTEN—urinary bladder cancer	8.68e-06	0.000193	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—CREBBP—urinary bladder cancer	8.66e-06	0.000193	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—IL2—urinary bladder cancer	8.59e-06	0.000191	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—SRC—urinary bladder cancer	8.57e-06	0.000191	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—ERBB2—urinary bladder cancer	8.55e-06	0.00019	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—IGF1—urinary bladder cancer	8.55e-06	0.00019	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—CREBBP—urinary bladder cancer	8.52e-06	0.00019	CbGpPWpGaD
Ergotamine—DRD2—Signaling by GPCR—EGFR—urinary bladder cancer	8.51e-06	0.000189	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—RHOA—urinary bladder cancer	8.49e-06	0.000189	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—IGF1—urinary bladder cancer	8.41e-06	0.000187	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—CCND1—urinary bladder cancer	8.37e-06	0.000186	CbGpPWpGaD
Ergotamine—HTR2A—Signaling by GPCR—EGFR—urinary bladder cancer	8.37e-06	0.000186	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—CREBBP—urinary bladder cancer	8.34e-06	0.000186	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—EP300—urinary bladder cancer	8.28e-06	0.000184	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—ERBB2—urinary bladder cancer	8.26e-06	0.000184	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—IGF1—urinary bladder cancer	8.24e-06	0.000183	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—MTHFR—urinary bladder cancer	8.23e-06	0.000183	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—ERBB2—urinary bladder cancer	8.21e-06	0.000183	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	8.2e-06	0.000183	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling by GPCR—EGFR—urinary bladder cancer	8.2e-06	0.000182	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—MMP9—urinary bladder cancer	8.13e-06	0.000181	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—CXCL8—urinary bladder cancer	8.11e-06	0.000181	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—CDKN1A—urinary bladder cancer	8.1e-06	0.00018	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—GSTP1—urinary bladder cancer	8.09e-06	0.00018	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—PTEN—urinary bladder cancer	8.08e-06	0.00018	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling by GPCR—HRAS—urinary bladder cancer	8.06e-06	0.000179	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—SRC—urinary bladder cancer	8.05e-06	0.000179	CbGpPWpGaD
Ergotamine—DRD2—Signaling by GPCR—KRAS—urinary bladder cancer	8.04e-06	0.000179	CbGpPWpGaD
Ergotamine—HTR2A—Signaling by GPCR—KRAS—urinary bladder cancer	7.91e-06	0.000176	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—ERBB2—urinary bladder cancer	7.86e-06	0.000175	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—MYC—urinary bladder cancer	7.85e-06	0.000175	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—RHOA—urinary bladder cancer	7.83e-06	0.000174	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—CXCL8—urinary bladder cancer	7.83e-06	0.000174	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	7.82e-06	0.000174	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—CXCL8—urinary bladder cancer	7.79e-06	0.000173	CbGpPWpGaD
Ergotamine—HTR1A—Signaling by GPCR—HRAS—urinary bladder cancer	7.78e-06	0.000173	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—IL2—urinary bladder cancer	7.75e-06	0.000173	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—CREBBP—urinary bladder cancer	7.75e-06	0.000172	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling by GPCR—KRAS—urinary bladder cancer	7.74e-06	0.000172	CbGpPWpGaD
Ergotamine—HTR2C—Signaling by GPCR—HRAS—urinary bladder cancer	7.74e-06	0.000172	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—RHOA—urinary bladder cancer	7.71e-06	0.000171	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—EP300—urinary bladder cancer	7.71e-06	0.000171	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—MYC—urinary bladder cancer	7.68e-06	0.000171	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—EGFR—urinary bladder cancer	7.67e-06	0.000171	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—IGF1—urinary bladder cancer	7.65e-06	0.00017	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling by GPCR—EGFR—urinary bladder cancer	7.62e-06	0.000169	CbGpPWpGaD
Ergotamine—ADRA2A—Metabolism—PTGS2—urinary bladder cancer	7.59e-06	0.000169	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—CCND1—urinary bladder cancer	7.56e-06	0.000168	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—RHOA—urinary bladder cancer	7.55e-06	0.000168	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—TYMS—urinary bladder cancer	7.52e-06	0.000167	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—EGFR—urinary bladder cancer	7.51e-06	0.000167	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—SRC—urinary bladder cancer	7.49e-06	0.000167	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—IL2—urinary bladder cancer	7.48e-06	0.000167	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—NQO1—urinary bladder cancer	7.48e-06	0.000167	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—CXCL8—urinary bladder cancer	7.46e-06	0.000166	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—IL2—urinary bladder cancer	7.45e-06	0.000166	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	7.43e-06	0.000165	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	7.43e-06	0.000165	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling by GPCR—HRAS—urinary bladder cancer	7.41e-06	0.000165	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—MMP9—urinary bladder cancer	7.34e-06	0.000163	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—CDKN1A—urinary bladder cancer	7.31e-06	0.000163	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—CCND1—urinary bladder cancer	7.3e-06	0.000162	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—PTEN—urinary bladder cancer	7.29e-06	0.000162	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—CCND1—urinary bladder cancer	7.26e-06	0.000162	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—ERBB2—urinary bladder cancer	7.25e-06	0.000161	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—KRAS—urinary bladder cancer	7.25e-06	0.000161	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—MYC—urinary bladder cancer	7.22e-06	0.000161	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling by GPCR—KRAS—urinary bladder cancer	7.19e-06	0.00016	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—ERBB2—urinary bladder cancer	7.13e-06	0.000159	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—IL2—urinary bladder cancer	7.13e-06	0.000159	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—GPX1—urinary bladder cancer	7.12e-06	0.000158	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—KRAS—urinary bladder cancer	7.1e-06	0.000158	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—MMP9—urinary bladder cancer	7.08e-06	0.000158	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—EGFR—urinary bladder cancer	7.06e-06	0.000157	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—CDKN1A—urinary bladder cancer	7.06e-06	0.000157	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—MMP9—urinary bladder cancer	7.05e-06	0.000157	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—PTEN—urinary bladder cancer	7.04e-06	0.000157	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—CDKN1A—urinary bladder cancer	7.02e-06	0.000156	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—RHOA—urinary bladder cancer	7.01e-06	0.000156	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—PTEN—urinary bladder cancer	7.01e-06	0.000156	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	6.99e-06	0.000155	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—ERBB2—urinary bladder cancer	6.98e-06	0.000155	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—EP300—urinary bladder cancer	6.96e-06	0.000155	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—CCND1—urinary bladder cancer	6.95e-06	0.000155	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—CXCL8—urinary bladder cancer	6.88e-06	0.000153	CbGpPWpGaD
Ergotamine—DRD2—Signaling by GPCR—HRAS—urinary bladder cancer	6.83e-06	0.000152	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—CXCL8—urinary bladder cancer	6.77e-06	0.000151	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—SRC—urinary bladder cancer	6.76e-06	0.000151	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—MMP9—urinary bladder cancer	6.75e-06	0.00015	CbGpPWpGaD
Ergotamine—HTR2A—Signaling by GPCR—HRAS—urinary bladder cancer	6.72e-06	0.00015	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—CDKN1A—urinary bladder cancer	6.72e-06	0.00015	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—EP300—urinary bladder cancer	6.72e-06	0.000149	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—MYC—urinary bladder cancer	6.71e-06	0.000149	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—PTEN—urinary bladder cancer	6.71e-06	0.000149	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—EP300—urinary bladder cancer	6.68e-06	0.000149	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—PPARG—urinary bladder cancer	6.67e-06	0.000148	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—KRAS—urinary bladder cancer	6.67e-06	0.000148	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—CXCL8—urinary bladder cancer	6.62e-06	0.000147	CbGpPWpGaD
Ergotamine—ADRA2A—Metabolism—PTEN—urinary bladder cancer	6.62e-06	0.000147	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling by GPCR—HRAS—urinary bladder cancer	6.58e-06	0.000146	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—IL2—urinary bladder cancer	6.57e-06	0.000146	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	6.57e-06	0.000146	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—EGFR—urinary bladder cancer	6.57e-06	0.000146	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—SRC—urinary bladder cancer	6.53e-06	0.000145	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—SRC—urinary bladder cancer	6.5e-06	0.000145	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—ERBB2—urinary bladder cancer	6.49e-06	0.000144	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—IL2—urinary bladder cancer	6.47e-06	0.000144	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—TP53—urinary bladder cancer	6.44e-06	0.000143	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—CREBBP—urinary bladder cancer	6.41e-06	0.000143	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—CCND1—urinary bladder cancer	6.41e-06	0.000143	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—EP300—urinary bladder cancer	6.4e-06	0.000142	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—IL2—urinary bladder cancer	6.33e-06	0.000141	CbGpPWpGaD
Ergotamine—ADRA2A—Metabolism—EP300—urinary bladder cancer	6.31e-06	0.00014	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—TP53—urinary bladder cancer	6.31e-06	0.00014	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—CCND1—urinary bladder cancer	6.3e-06	0.00014	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	6.24e-06	0.000139	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—SRC—urinary bladder cancer	6.22e-06	0.000138	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—MMP9—urinary bladder cancer	6.22e-06	0.000138	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—KRAS—urinary bladder cancer	6.2e-06	0.000138	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—CDKN1A—urinary bladder cancer	6.2e-06	0.000138	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—PTEN—urinary bladder cancer	6.18e-06	0.000138	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—CCND1—urinary bladder cancer	6.17e-06	0.000137	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—HRAS—urinary bladder cancer	6.16e-06	0.000137	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—CXCL8—urinary bladder cancer	6.15e-06	0.000137	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—MMP9—urinary bladder cancer	6.12e-06	0.000136	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling by GPCR—HRAS—urinary bladder cancer	6.11e-06	0.000136	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—CDKN1A—urinary bladder cancer	6.1e-06	0.000136	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—PTEN—urinary bladder cancer	6.08e-06	0.000135	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—MYC—urinary bladder cancer	6.06e-06	0.000135	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—HRAS—urinary bladder cancer	6.03e-06	0.000134	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—MMP9—urinary bladder cancer	5.99e-06	0.000133	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—CDKN1A—urinary bladder cancer	5.97e-06	0.000133	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—PTEN—urinary bladder cancer	5.96e-06	0.000133	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—EGFR—urinary bladder cancer	5.93e-06	0.000132	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—TP53—urinary bladder cancer	5.93e-06	0.000132	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—EP300—urinary bladder cancer	5.9e-06	0.000131	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—IL2—urinary bladder cancer	5.88e-06	0.000131	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—MYC—urinary bladder cancer	5.85e-06	0.00013	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—MYC—urinary bladder cancer	5.82e-06	0.00013	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—TYMS—urinary bladder cancer	5.8e-06	0.000129	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—EP300—urinary bladder cancer	5.8e-06	0.000129	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	5.74e-06	0.000128	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	5.74e-06	0.000128	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—CCND1—urinary bladder cancer	5.73e-06	0.000128	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—SRC—urinary bladder cancer	5.73e-06	0.000128	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—EGFR—urinary bladder cancer	5.72e-06	0.000127	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—EGFR—urinary bladder cancer	5.69e-06	0.000127	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—EP300—urinary bladder cancer	5.68e-06	0.000126	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—HRAS—urinary bladder cancer	5.67e-06	0.000126	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—SRC—urinary bladder cancer	5.64e-06	0.000126	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—KRAS—urinary bladder cancer	5.6e-06	0.000125	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—MYC—urinary bladder cancer	5.57e-06	0.000124	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—MMP9—urinary bladder cancer	5.57e-06	0.000124	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—CDKN1A—urinary bladder cancer	5.55e-06	0.000123	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—PTEN—urinary bladder cancer	5.53e-06	0.000123	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—SRC—urinary bladder cancer	5.52e-06	0.000123	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—TP53—urinary bladder cancer	5.51e-06	0.000123	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—GPX1—urinary bladder cancer	5.49e-06	0.000122	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—EGFR—urinary bladder cancer	5.45e-06	0.000121	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—KRAS—urinary bladder cancer	5.41e-06	0.00012	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	5.39e-06	0.00012	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—KRAS—urinary bladder cancer	5.38e-06	0.00012	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—PPARG—urinary bladder cancer	5.33e-06	0.000119	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—EP300—urinary bladder cancer	5.28e-06	0.000117	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—HRAS—urinary bladder cancer	5.27e-06	0.000117	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—PTGS2—urinary bladder cancer	5.25e-06	0.000117	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—KRAS—urinary bladder cancer	5.15e-06	0.000115	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—MYC—urinary bladder cancer	5.14e-06	0.000114	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—SRC—urinary bladder cancer	5.13e-06	0.000114	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	5.12e-06	0.000114	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	5.07e-06	0.000113	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—MYC—urinary bladder cancer	5.06e-06	0.000112	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—EGFR—urinary bladder cancer	5.03e-06	0.000112	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—TP53—urinary bladder cancer	4.98e-06	0.000111	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—MYC—urinary bladder cancer	4.95e-06	0.00011	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—EGFR—urinary bladder cancer	4.94e-06	0.00011	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—EGFR—urinary bladder cancer	4.84e-06	0.000108	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—TP53—urinary bladder cancer	4.81e-06	0.000107	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—TP53—urinary bladder cancer	4.78e-06	0.000106	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—HRAS—urinary bladder cancer	4.76e-06	0.000106	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—KRAS—urinary bladder cancer	4.75e-06	0.000106	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—KRAS—urinary bladder cancer	4.67e-06	0.000104	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—MYC—urinary bladder cancer	4.6e-06	0.000102	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—HRAS—urinary bladder cancer	4.6e-06	0.000102	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—PTEN—urinary bladder cancer	4.58e-06	0.000102	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—TP53—urinary bladder cancer	4.58e-06	0.000102	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—KRAS—urinary bladder cancer	4.57e-06	0.000102	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—HRAS—urinary bladder cancer	4.57e-06	0.000102	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—EGFR—urinary bladder cancer	4.5e-06	0.0001	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—HRAS—urinary bladder cancer	4.38e-06	9.74e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—EP300—urinary bladder cancer	4.36e-06	9.71e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—KRAS—urinary bladder cancer	4.25e-06	9.46e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—TP53—urinary bladder cancer	4.22e-06	9.39e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	4.19e-06	9.32e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—TP53—urinary bladder cancer	4.15e-06	9.24e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—PPARG—urinary bladder cancer	4.11e-06	9.15e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—TP53—urinary bladder cancer	4.07e-06	9.05e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—HRAS—urinary bladder cancer	4.04e-06	8.98e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—HRAS—urinary bladder cancer	3.97e-06	8.83e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	3.95e-06	8.79e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—HRAS—urinary bladder cancer	3.89e-06	8.65e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—TP53—urinary bladder cancer	3.78e-06	8.4e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—PTEN—urinary bladder cancer	3.65e-06	8.13e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—HRAS—urinary bladder cancer	3.61e-06	8.04e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—EP300—urinary bladder cancer	3.48e-06	7.75e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	3.23e-06	7.19e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—PTEN—urinary bladder cancer	2.82e-06	6.27e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—EP300—urinary bladder cancer	2.69e-06	5.98e-05	CbGpPWpGaD
